Ocular Therapeutix (OCUL) Gains from Investment Securities (2013 - 2014)

Ocular Therapeutix's (OCUL) quarterly Gains from Investment Securities came in at $108000.0 in Q3 2014, up 3700.0% year-on-year from $2842.1 in Q3 2013, and down 17.56% quarter-over-quarter from $131000.0 in Q2 2014.

Ocular Therapeutix (OCUL) Gains from Investment Securities (2013 - 2014) Analysis & Trends

Ocular Therapeutix's Gains from Investment Securities history runs 2 years deep, the most recent figure standing at $108000.0 for Q3 2014.

  • On a quarterly basis, Gains from Investment Securities rose 3700.0% year-over-year to $108000.0 in Q3 2014; TTM through Dec 2014 was $380000.0, a N/A change from a year earlier, with the FY2014 full-year figure at $380000.0, up 2814.29% from the prior year.
  • Gains from Investment Securities slipped to $108000.0 in Q3 2014 per OCUL's latest filing, from $131000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $141000.0 in Q1 2014 and bottomed at -$4000.0 in Q4 2013.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,042.03 Bn 67,041.74 Bn -
2 Nanobiotix 1,911.83 Bn 1,911.77 Bn -
3 Akari Therapeutics 989.71 Bn 989.71 Bn -
4 BeOne Medicines 471.62 Bn 466.83 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.97 Bn 114.72 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.98 Bn 61.22 Bn 3.31 Bn
7 Belite Bio 62.68 Bn 62.68 Bn -
8 Argenx Se 55.75 Bn 50.57 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.49 Bn 34.48 Bn 959.66 Mn
10 Ocular Therapeutix 1.94 Bn 1.94 Bn 9.46 Mn

Historic Data

Download Data
DateValue
Sep 30, 2014 108,000.00
Sep 30, 2014 108,000.00
Jun 30, 2014 131,000.00
Jun 30, 2014 131,000.00
Mar 31, 2014 141,000.00
Mar 31, 2014 141,000.00
Dec 31, 2013 -4,000.00
Dec 31, 2013 -4,000.00
Sep 30, 2013 -3,000.00
Sep 30, 2013 -3,000.00